3 recruiting, 2 active not recruiting, 1 completed. 4 Phase 1, 3 Phase 2, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Completed 1 |
| Phase 2 | 3 | Recruiting 3 |
| Early Phase 1 | 2 | Active not recruiting 2 |
Follow Perspective Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lead-212 PSV359 Therapy for Patients With Solid Tumors [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 - Pancreatic Ductal Adenocarcinoma, Gastric Cancer | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 112 | 2025-04-28 | 2026-10-28 |
| A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT - Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung | Early Phase 1 | Active not recruiting | David Bushnell | 24 | 2023-11-10 | 2025-11-04 |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors [203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-09-27 | 2026-10-13 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent [203Pb]VMT-α-NET, SPECT/CT - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 | Early Phase 1 | Active not recruiting | Yusuf Menda | 20 | 2022-08-22 | 2025-07-14 |
| Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy [203Pb]VMT01, [68Ga]VMT02 - Melanoma (Skin), Melanoma Stage IV | Phase 1 | Completed | Perspective Therapeutics | 7 | 2021-03-05 | 2023-11-07 |
Melanoma (2) · Neuroendocrine Tumors (2) · Adenoma, Islet Cell (1) · Colorectal Neoplasms (1) · Disease (1) · Esophageal Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Head and Neck Neoplasms (1) · Meningioma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Paraganglioma (1) · Pheochromocytoma (1)
Nivolumab (1) · Single Photon Emission Computed Tomography Computed Tomography (1)
United States (6)
David Bushnell, MD (1) · Frances L Johnson, MD (1) · Geoffrey B Johnson, MD, PhD (1) · Yusuf Menda, M.D. (1)
R01CA243014 (2)